Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
34.98% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-46.86% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Gyre Therapeutics |
554.75 Mn |
540.62 Mn |
8.38 Mn |
-80.42% |
| Date | Value |
|---|
| Mar 31, 2026 |
-80.42% |
| Dec 31, 2025 |
61.38% |
| Sep 30, 2025 |
39.92% |
| Jun 30, 2025 |
-79.54% |
| Mar 31, 2025 |
29.77% |
| Dec 31, 2024 |
83.04% |
| Sep 30, 2024 |
26.92% |
| Jun 30, 2024 |
29.61% |
| Mar 31, 2024 |
32.68% |
| Dec 31, 2023 |
-74.81% |
| Sep 30, 2023 |
31.00% |
| Jun 30, 2023 |
28.21% |
| Mar 31, 2023 |
36.69% |
| Dec 31, 2022 |
-30.01% |
| Sep 30, 2022 |
27.29% |
| Jun 30, 2022 |
79.12% |
| Mar 31, 2022 |
1.22% |
| Dec 31, 2021 |
-23.29% |
| Sep 30, 2021 |
-48.58% |
| Jun 30, 2021 |
-45.41% |
